首页> 外文期刊>Poiesis & praxis >Biomedical and bioethical issues in Parliamentary TA and in Health Technology Assessment
【24h】

Biomedical and bioethical issues in Parliamentary TA and in Health Technology Assessment

机译:议会技术援助和卫生技术评估中的生物医学和生物伦理问题

获取原文
获取原文并翻译 | 示例
       

摘要

HTA and TA institutions at national parliaments (PTA) both share the same origin and of course have objectives and some of their methods in common. Nevertheless both TA branches developed in some distance during the 1970s and 1980s. Drawing on the case of biomedicine this paper outlines the differences between HTA and PTA, highlighting the clinical perspective of HTA and the "societal perspective" of PTA. It is shown that biomedicine which has developed rapidly during the last decade has hardly been dealt with by HTA, whereas it ranked quite prominent on the agendas of PTA institutions. Biomedical technologies became a subject of policy making beyond the boundaries of health care politics since biomedicine is perceived as an ethical challenge to society and not only as a medical innovation that has to be assessed by clinical experts. It is argued that there may however be good reasons to integrate the HTA and the PTA perspective in future TA on biomedical technologies.
机译:各国议会(PTA)的HTA和TA机构都具有相同的起源,当然也有目标和某些共同点。但是,两个TA分支在1970年代和1980年代都有一定距离的发展。本文以生物医学为例,概述了HTA和PTA之间的区别,强调了HTA的临床观点和PTA的“社会观点”。研究表明,在过去十年中发展迅速的生物医学几乎没有被HTA处理,而在PTA机构的议程中,它却是相当重要的。由于生物医学被视为对社会的伦理挑战,而不仅是必须由临床专家评估的医学创新,因此生物医学技术已成为医疗保健政治范围之外的政策制定主题。有人认为,然而,可能有充分的理由将HTA和PTA观点纳入未来的生物医学技术技术援助中。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号